{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:26:52Z","timestamp":1774466812928,"version":"3.50.1"},"reference-count":29,"publisher":"Akademiai Kiado Zrt.","issue":"42","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,10,17]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> B\u00e1r a figyelemhi\u00e1nyos hiperaktivit\u00e1si zavar kezel\u00e9se\n                    sor\u00e1n alkalmazott metilfenid\u00e1t-monoter\u00e1pi\u00e1val \u00f6sszef\u00fcgg\u00e9sben jelentkez\u0151\n                    gynaecomasti\u00e1r\u00f3l bizonyos nemk\u00edv\u00e1natos hat\u00e1sok adatb\u00e1zisai besz\u00e1molnak, a\n                    szakirodalom \u00e1ttekint\u00e9se alapj\u00e1n ez id\u00e1ig mind\u00f6ssze 5 esettanulm\u00e1nyt publik\u00e1ltak\n                    a t\u00e9m\u00e1ban. Tanulm\u00e1nyunkban egy autizmusspektrum-zavarral \u00e9s figyelemhi\u00e1nyos\n                    hiperaktivit\u00e1si zavarral egyar\u00e1nt diagnosztiz\u00e1lt gyermek eset\u00e9t mutatjuk be,\n                    akin\u00e9l 6 h\u00f3napon \u00e1t tart\u00f3, folyamatos metilfenid\u00e1t-monoter\u00e1pi\u00e1j\u00e1val\n                    \u00f6sszef\u00fcgg\u00e9sben k\u00e9toldali gynaecomastia kialakul\u00e1s\u00e1t tapasztaltuk. A kezel\u00e9s\n                    azonnali le\u00e1ll\u00edt\u00e1sa mellett 10 napos klomif\u00e9nkezel\u00e9s t\u00f6rt\u00e9nt. A\n                    metilfenid\u00e1t-ter\u00e1pia azonnali le\u00e1ll\u00edt\u00e1s\u00e1t k\u00f6vet\u0151en 14 nappal a gynaecomastia\n                    mindk\u00e9t oldalon visszah\u00faz\u00f3dott. 3 h\u00f3napos, gyermekpszichi\u00e1triai szempontb\u00f3l\n                    gy\u00f3gyszermentes id\u0151szakot k\u00f6vet\u0151en a metilfenid\u00e1t-ter\u00e1pia \u00fajraind\u00edt\u00e1sa t\u00f6rt\u00e9nt,\n                    de 1 h\u00f3nap eltelt\u00e9vel a nem k\u00edv\u00e1nt mell\u00e9khat\u00e1s ism\u00e9t jelentkezett. A\n                    metilfenid\u00e1t-ter\u00e1pia \u00e9s a gynaecomastia kialakul\u00e1sa k\u00f6z\u00f6tti kapcsolat sz\u00e1mos\n                    mechanizmussal kapcsolatban k\u00e9rd\u00e9seket vet fel. Gyermekpszichi\u00e1triai szempontb\u00f3l\n                    \u00e9rdekes k\u00e9rd\u00e9s, hogy relev\u00e1ns lehet-e a gy\u00f3gyszeres ter\u00e1pia k\u00f6vetkezm\u00e9nyek\u00e9nt\n                    kialakul\u00f3 nemk\u00edv\u00e1natos mell\u00e9khat\u00e1s megjelen\u00e9s\u00e9ben az autizmusspektrum-zavar \u00e9s a\n                    figyelemhi\u00e1nyos hiperaktivit\u00e1si zavar komorbid fenn\u00e1ll\u00e1sa. A jelens\u00e9g h\u00e1tter\u00e9ben\n                    felmer\u00fcl tov\u00e1bb\u00e1 a neuroendokrin-immunol\u00f3giai rendszer szab\u00e1lyoz\u00e1s\u00e1nak esetleges\n                    megv\u00e1ltoz\u00e1sa. Esettanulm\u00e1nyunk felh\u00edvja a gyakorl\u00f3 orvoskoll\u00e9g\u00e1k figyelm\u00e9t a\n                    metilfenid\u00e1t-ter\u00e1pia alkalmaz\u00e1sa mellett potenci\u00e1lisan kialakul\u00f3 gynaecomastia\n                    monitoroz\u00e1s\u00e1ra. Orv Hetil. 2021; 162(42): 1703\u20131708.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> Although gynecomastia associated with methylphenidate\n                    monotherapy in the treatment of attention deficit hyperactivity disorder has\n                    already been reported in some adverse event databases, based on a review of the\n                    literature it appears that only five case reports have been published. In our\n                    study, we present the case of a child diagnosed with both autism spectrum\n                    disorder and attention deficit\/hyperactivity disorder, who developed bilateral\n                    gynecomastia in association with continuous methylphenidate monotherapy for 6\n                    months. With immediate cessation of methylphenidate therapy, clomiphene\n                    treatment was given for 10 days. A total of 14 days after cessation of\n                    methylphenidate treatment gynecomastia receded on both sides. After a\n                    methylphenidate drug-free period of 3 months, methylphenidate therapy was\n                    restarted, but 1 month later the side effect reappeared. The relationship\n                    between methylphenidate and the development of gynecomastia raises questions\n                    about a number of mechanisms. From a child psychiatrist point of view, it is an\n                    interesting question whether the presence of comorbid autism spectrum disorder\n                    and attention deficit\/hyperactivity disorder may be relevant in the onset of\n                    adverse events by medication. The phenomenon may also be caused by altered\n                    regulation of the neuroendocrine-immune system. Our case report draws the\n                    attention of practicing physicians to monitoring of potential gynecomastia\n                    during methylphenidate therapy. Orv Hetil. 2021; 162(42): 1703\u20131708.<\/jats:p>","DOI":"10.1556\/650.2021.32198","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T13:22:52Z","timestamp":1639401772000},"page":"1703-1708","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["Lehets\u00e9ges \u00f6sszef\u00fcgg\u00e9s egy autizmusspektrum-zavarban \u00e9rintett gyermek metilfenid\u00e1t-kezel\u00e9se \u00e9s az azt k\u00f6vet\u0151en kialakult gynaecomastia k\u00f6z\u00f6tt"],"prefix":"10.1556","volume":"162","author":[{"given":"N\u00f3ra","family":"Koll\u00e1rovics","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, Ment\u00e1lis Eg\u00e9szs\u00e9gtudom\u00e1nyok Doktori Iskola, Pszichi\u00e1tria Program, Gyermekpszichi\u00e1triai K\u00f3rk\u00e9pek Vizsg\u00e1lata Munkacsoport, Budapest"},{"name":"Nemzetk\u00f6zi Csepered\u0151 Alap\u00edtv\u00e1ny, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Nagy","sequence":"additional","affiliation":[{"name":"Bethesda Gyermekk\u00f3rh\u00e1z, Figyelemhi\u00e1nyos Hiperaktivit\u00e1s Zavar (ADHD) Ambulancia, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Bal\u00e1zs","sequence":"additional","affiliation":[{"name":"E\u00f6tv\u00f6s Lor\u00e1nd Tudom\u00e1nyegyetem, Pedag\u00f3giai \u00e9s Pszichol\u00f3giai Kar, Pszichol\u00f3giai Int\u00e9zet, Fejl\u0151d\u00e9s- \u00e9s Klinikai Gyermekpszichol\u00f3gia Tansz\u00e9k, Budapest"},{"name":"Bj\u00f8rknes University College, Oslo, Norv\u00e9gia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1017\/S0816512200027358","article-title":"The North American Perspective on attention deficit hyperactivity disorder","volume":"13","author":"1 Barkley","year":"1996","unstructured":"1 Barkley RA. The North American Perspective on attention deficit hyperactivity disorder. J Aust Educ Develop Psychol. 1996; 13: 2-23.","journal-title":"J Aust Educ Develop Psychol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/A:1017494719205","article-title":"January 2002","volume":"5","author":"2 Barkley","year":"2002","unstructured":"2 Barkley RA, Cook EH, Diamond A, et al. International consensus statement on ADHD. January 2002. Clin Child Fam Psychol Rev. 2002; 5: 89-111.","journal-title":"Clin Child Fam Psychol Rev"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3 Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit\/hyperactivity disorder in primary care settings. Pediatrics 2001; 107: E43.","DOI":"10.1542\/peds.107.3.e43"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0924-977X(03)00045-2","article-title":"International consensus statement on attention-deficit\/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions","volume":"14","author":"4 Kutcher","year":"2004","unstructured":"4 Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit\/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004; 14: 11-28.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Santosh PJ, Taylor E. Stimulant drugs. Eur Child Adolesc Psychiatry 2000; 9: S27.","DOI":"10.1007\/s007870070017"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology","volume":"32","author":"6 Howes","year":"2018","unstructured":"6 Howes OD, Rogdaki M, Findon JL, et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol. 2018; 32: 3-29.","journal-title":"J Psychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14740338.2017.1301928","article-title":"An update on the safety of psychostimulants for the treatment of attention-deficit\/hyperactivity disorder","volume":"16","author":"7 Groenman","year":"2017","unstructured":"7 Groenman AP, Schweren LJ, Dietrich A, et al. An update on the safety of psychostimulants for the treatment of attention-deficit\/hyperactivity disorder. Expert Opin Drug Saf. 2017; 16: 455-464.","journal-title":"Expert Opin Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/MOP.0b013e328306a07c","article-title":"Gynecomastia in adolescents","volume":"20","author":"Nordt CA","year":"2008","unstructured":"8 Nordt CA, DiVasta AD. Gynecomastia in adolescents. Curr Opin Pediatr. 2008; 20: 375-382.","journal-title":"Curr Opin Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0025-6196(11)60671-X","article-title":"Gynecomastia: pathophysiology, evaluation, and management","volume":"84","author":"Johnson RE","year":"2009","unstructured":"9 Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc. 2009; 84: 1010-1015.","journal-title":"Mayo Clin Proc"},{"key":"ref9","unstructured":"10 Goldman RD. Drug-induced gynecomastia in children and adolescents. Can Fam Physician 2010; 56: 344-345."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/phar.1138","article-title":"Drug-induced gynecomastia","volume":"32","author":"11 Bowman","year":"2012","unstructured":"11 Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy 2012; 32: 1123-1140.","journal-title":"Pharmacotherapy"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Maciejewski M, Lounkine E, Whitebread S, et al. The powers and perils of post-marketing data analysis: quantification and mitigation of biases in the FDA Adverse Event Reporting System. bioRxiv 2016; 068692.","DOI":"10.1101\/068692"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00238-010-0469-6","article-title":"Prepubertal unilateral gynecomastia: a report of two cases","volume":"34","author":"13 Hoevenaren","year":"2011","unstructured":"13 Hoevenaren IA, Schott DA, Otten BJ, et al. Prepubertal unilateral gynecomastia: a report of two cases. Eur J Plast Surg. 2011; 34: 395-398.","journal-title":"Eur J Plast Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00431-011-1546-y","article-title":"Unilateral gynecomastia in a prepubertal boy","volume":"171","author":"14 Ensat","year":"2012","unstructured":"14 Ensat F, Edelbauer M, Wechselberger G. Unilateral gynecomastia in a prepubertal boy. Eur J Pediatr. 2012; 171: 197.","journal-title":"Eur J Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JCP.0000000000000141","article-title":"Bilateral gynecomastia in a preadolescent boy while under treatment with methylphenidate and paroxetine","volume":"34","author":"15 Coskun","year":"2014","unstructured":"15 Coskun M, Adak I, Akaltun I. Bilateral gynecomastia in a preadolescent boy while under treatment with methylphenidate and paroxetine. J Clin Psychopharmacol. 2014; 34: 537-538.","journal-title":"J Clin Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16 Almis BH, Almis H, Celik M, et al. Methylphenidate induced gynecomastia in a prepubertal boy: a case report. Anatolian J Psychiatry 2016; 17(Suppl 3): 74-76.","DOI":"10.5455\/apd.177010"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.9758\/cpn.2020.18.2.337","article-title":"Gynecomastia: a rare adverse effect of methylphenidate in an adolescent boy","volume":"18","author":"17 Karayagmurlu","year":"2020","unstructured":"17 Karayagmurlu A, Varli AT, Coskun M. Gynecomastia: a rare adverse effect of methylphenidate in an adolescent boy. Clin Psychopharmacol Neurosci. 2020; 18: 337-339.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4088\/JCP.09m05305whi","article-title":"Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)","volume":"71","author":"18 Sheehan","year":"2010","unstructured":"18 Sheehan DV, Sheehan KH, Shytle RD, et al. Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). J Clin Psychiatry 2010; 71: 313-326.","journal-title":"J Clin Psychiatry"},{"key":"ref18","unstructured":"19 Bal\u00e1zs J, Bitter I, Hideg K, et al. The Hungarian version of the MINI and MINI Plus. [A MINI \u00e9s a MINI Plusz k\u00e9rdo\u030b\u00edv magyar nyelvu\u030b v\u00e1ltozat\u00e1nak kidolgoz\u00e1sa.] Psychiatr Hung. 1998; 13: 160-168. [Hungarian]"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. Guilford Press, New York, NY, 1998.","DOI":"10.1037\/t00680-000"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1469-7610.1997.tb01545.x","article-title":"The Strengths and Difficulties Questionnaire: a research note","volume":"38","author":"21 Goodman","year":"1997","unstructured":"21 Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 1997; 38: 581-586.","journal-title":"J Child Psychol Psychiatry"},{"key":"ref21","unstructured":"22 T\u00fari E, Gervai J, \u00c1sp\u00e1n N, et al. Validation of the Hungarian version of the Strengths and Difficulties Questionnaire in an adolescent clinical population. [A K\u00e9pess\u00e9gek \u00e9s Neh\u00e9zs\u00e9gek K\u00e9rd\u0151\u00edv (SDQ-Magy) valid\u00e1l\u00e1sa serd\u00fcl\u0151kor\u00fa klinikai popul\u00e1ci\u00f3ban.] Psychiatr Hung. 2013; 28: 165-179. [Hungarian]"},{"key":"ref22","unstructured":"23 Food and Drug Administration. Label of methylphenidate. FDA, Silver Spring, MD, 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/010187s077lbl.pdf [accessed: March 15, 2021]."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fifth edition. American Psychiatric Association, Washington, DC, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"25 Posey","year":"2007","unstructured":"25 Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007; 61: 538-544.","journal-title":"Biol Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1001572","DOI":"10.1371\/journal.pmed.1001572","article-title":"Non-specialist psychosocial interventions for children and adolescents with intellectual disability or lower-functioning autism spectrum disorders: a systematic review","volume":"10","author":"26 Reichow","year":"2013","unstructured":"26 Reichow B, Servili C, Yasamy MT, et al. Non-specialist psychosocial interventions for children and adolescents with intellectual disability or lower-functioning autism spectrum disorders: a systematic review. PLoS Med. 2013; 10: 1001572.","journal-title":"PLoS Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1258\/0004563011900993","article-title":"Endocrinology of gynaecomastia","volume":"38","author":"Ismail AA","year":"2001","unstructured":"27 Ismail AA, Barth JH. Endocrinology of gynaecomastia. Ann Clin Biochem. 2001; 38: 596-607.","journal-title":"Ann Clin Biochem"},{"key":"ref27","unstructured":"28 Braunstein GD, Glassman HA. Gynecomastia. Curr Ther Endocrinol Metab. 1997; 6: 401-404."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1196\/annals.1369.005","article-title":"Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual\/endocrine parameters in male rats","volume":"1074","author":"29 Adriani","year":"2006","unstructured":"29 Adriani W, Leo D, Guarino M, et al. Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual\/endocrine parameters in male rats. Ann N Y Acad Sci. 2006; 1074: 52-73.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/42\/article-p1703.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/42\/article-p1703.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/42\/article-p1703.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T13:17:25Z","timestamp":1698412645000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/42\/article-p1703.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":29,"journal-issue":{"issue":"42"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32198","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]}}}